Kaitlyn D’Onofrio

DocwireNews

During the second annual Houston Shock Symposium, Parvathi Mudigonda, MD, a cardiology fellow at the University of Cincinnati, presented a case study on a patient with giant cell myocarditis (GCM). The patient had a successful recovery with left ventricular support alone.GCM, Dr. Mudigonda explained, is a rare cause of fulminant myocarditis often associated with infectious and autoimmune diseases. In addition to fulminant myocarditis, other clinical features of GCM include cardiogenic shock, biventricular failure, ventricular arrhythmias, and heart block. Without transplantation, it is often fatal.Giant cells &ldquo;are very large cells with a large amount of cytoplasm and peripherally clustered nuclei either in a horseshoe shape or circumferentially,&rdquo; Dr. Mudigonda said.&ldquo;When histiocytes, which are tissue macrophages, are overwhelmed trying to phagocytose their target, they basically call for backup and fuse together,&rdquo; she said. GCM may be mistaken for sarcoid, but in GCM, the amount of necrosis is significantly greater than the poorly formed granulomas.The present patient was a 62-year-old black female regularly seeing her primary care provider, with mild comorbidities including type 2 diabetes mellitus, hyperlipidemia, morbid obesity, and borderline hypertension. The patient is a former smoker who now uses an electronic cigarette. The patient presented at the onset of flu season with symptoms including new onset of cough, wheezing, exertional dyspnea, orthopnea, and severe fatigue. Her primary doctor treated her with a Zpak and steroid taper. The initial treatment was ineffective, and within hours of presenting to an outside hospital with new onset heart failure, the patient progressed to fulminant cardiogenic shock. An echocardiography revealed severe biventricular dysfunction with mild left ventricular hypertrophy (LVH). She was eventually transferred to Dr. Mudigonda&rsquo;s institution, with worsening shock and rising troponin.&ldquo;She was started on dual inotrope support with milrinone and dobutamine, and she had some marginal improvement for about 36 hours,&rdquo; Dr. Mudigonda said. He then said she progressed to refractory cardiogenic shock; her urine output began tapering, and her Lactate elevated.The patient&rsquo;s presentation indicated that she may have had fulminant myocarditis, and she received intravenous high dose steroids on day three. A multidisciplinary discussion regarding serious treatment options &ldquo;eventually boiled down to either [extracorporeal membrane oxygenation {ECMO}] or [left ventricular assist device {LVAD}],&rdquo; Dr. Mudigonda said. &ldquo;Given the low likelihood of improvement within the next ten days, and even lower chance of obtaining a donor heart, the decision was made to proceed directly to durable LVAD support.&rdquo; On day four, the patient received a HeartMate II.After it was confirmed that the patient had GCM, she began receiving cyclosporine in addition to the 40 mg daily dose of prednisone she was already taking. During recovery, she sustained severe right ventricular failure, which improved significantly in one month after treatment with pulmonary vasodilators. Within two months, left ventricular function normalized.&ldquo;What was initially a bridge to transplantation became a bridge to recovery,&rdquo; Dr. Mudigonda said.The discovery of a renal mass changed the course of immunosuppression to 20 mg daily of prednisone. But today, six months later, the patient is alive and home, doing well in cardiac rehab with a good quality of life. Current discussions focus on removing her renal mass.

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

Case Study: Could LV Support for GCM Be a Bridge to Recovery?

Houston's Shock Symposium 2019

During the second annual Houston Shock Symposium, Parvathi Mudigonda, MD, a cardiology fellow at the University of Cincinnati, presented a case study on a patient with giant ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe